5-[[1-[5-[3-(azetidin-1-yl)pyrrolidin-1-yl]-2-pyridinyl]imidazol-4-yl]amino]pyrazine-2-carbonitrile
C20H21N9 — CID 171101715
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[[1-[5-[3-(azetidin-1-yl)pyrrolidin-1-yl]-2-pyridinyl]imidazol-4-yl]amino]pyrazine-2-carbonitrile
5-[[1-[5-[3-(azetidin-1-yl)pyrrolidin-1-yl]-2-pyridinyl]imidazol-4-yl]amino]pyrazine-2-carbonitrile (PubChem CID 171101715) has the molecular formula C20H21N9 and a molecular weight of 387.45 g/mol. Its IUPAC name is 5-[[1-[5-[3-(azetidin-1-yl)pyrrolidin-1-yl]-2-pyridinyl]imidazol-4-yl]amino]pyrazine-2-carbonitrile.
Molecular Properties
| Compound Name | 5-[[1-[5-[3-(azetidin-1-yl)pyrrolidin-1-yl]-2-pyridinyl]imidazol-4-yl]amino]pyrazine-2-carbonitrile |
|---|---|
| PubChem CID | 171101715 |
| Molecular Formula | C20H21N9 |
| Molecular Weight | 387.45 g/mol |
| Exact Mass | 387.19 |
| IUPAC Name | 5-[[1-[5-[3-(azetidin-1-yl)pyrrolidin-1-yl]-2-pyridinyl]imidazol-4-yl]amino]pyrazine-2-carbonitrile |
| SMILES | N#Cc1cnc(Nc2cn(-c3ccc(N4CCC(N5CCC5)C4)cn3)cn2)cn1 |
| InChI | InChI=1S/C20H21N9/c21-8-15-9-23-18(11-22-15)26-19-13-29(14-25-19)20-3-2-16(10-24-20)28-7-4-17(12-28)27-5-1-6-27/h2-3,9-11,13-14,17H,1,4-7,12H2,(H,23,26) |
| InChIKey | AYHYGTMNJQUXDM-UHFFFAOYSA-N |
| XLogP | 1.96 |
| TPSA | 98.79 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 387.45 |
| LogP ≤ 5 | 1.96 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171101715 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.